Oragenics, Inc.
OGEN Healthcare Biotechnology
Oragenics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $37,700.00, down 71.3% from fiscal 2022. In the quarter to June 2026, EPS grew 81.6% and free cash flow fell 66.4%, each against the same quarter a year earlier.
Follow OGEN
Oragenics, Inc. (OGEN) EV/Sales
As of 16 October 2026, Oragenics, Inc. (OGEN) trades at a EV/Sales of 3.6×. Over the past ten years it has ranged from −63.3× (December 2025) to 115× (January 2024); the current reading is higher than 21% of that period. That is below the Biotechnology industry median of 9.2× and in line with the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 114× | 360.88% |
| FY2022 | 24.8× | (21.38%) |
| FY2021 | 31.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2023 | 31.0× | 73.75% |
| Jun 2023 | 17.9× | 445.57% |
| Mar 2023 | 3.3× | (95.32%) |
| Sep 2022 | 69.9× | 37.52% |
| 4 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SILO Silo Pharma, Inc. compare | −54.6× |
| BRTX Biorestorative Therapies, Inc. compare | −5.7× |
| CLSDQ Clearside Biomedical, Inc. compare | −1.2× |
| GNPX GENPREX compare | n/m |
| PPBT Purple Biotech Ltd. Sponsored ADR compare | n/m |
| KAPA Kairos Pharma, Ltd. compare | n/m |
| VRAX Virax Biolabs Group Limited compare | n/m |
| OGEN Oragenics, Inc. | 3.6× |
| TRVN Trevena, Inc. compare | 35.0× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)